Aclara

Aclara Biosciences was a biotechnology company specializing in high-throughput, multiplexed assay technologies for protein and gene analysis. The company's flagship platform, the eTag assay system, allowed for the precise measurement of protein-protein interactions and protein activation states, such as phosphorylation. This technology was particularly influential in oncology, where it was used to develop personalized medicine diagnostics to predict patient response to targeted therapies. Aclara's approach combined microfluidics with proprietary chemical tags to provide detailed molecular profiles from clinical samples. In 2004, the company was acquired by Monogram Biosciences to integrate its proteomics platform with Monogram's existing molecular diagnostic capabilities.